Document Detail

A low dose of fermented soy germ alleviates gut barrier injury, hyperalgesia and faecal protease activity in a rat model of inflammatory bowel disease.
MedLine Citation:
PMID:  23166707     Owner:  NLM     Status:  MEDLINE    
Pro-inflammatory cytokines like macrophage migration inhibitory factor (MIF), IL-1β and TNF-α predominate in inflammatory bowel diseases (IBD) and TNBS colitis. Increased levels of serine proteases activating protease-activated receptor 2 (PAR-2) are found in the lumen and colonic tissue of IBD patients. PAR-2 activity and pro-inflammatory cytokines impair epithelial barrier, facilitating the uptake of luminal aggressors that perpetuate inflammation and visceral pain. Soy extracts contain phytoestrogens (isoflavones) and serine protease inhibitors namely Bowman-Birk Inhibitors (BBI). Since estrogens exhibit anti-inflammatory and epithelial barrier enhancing properties, and that a BBI concentrate improves ulcerative colitis, we aimed to evaluate if a fermented soy germ extract (FSG) with standardized isoflavone profile and stable BBI content exert cumulative or synergistic protection based on protease inhibition and estrogen receptor (ER)-ligand activity in colitic rats. Female rats received orally for 15 d either vehicle or FSG with or without an ER antagonist ICI 182.780 before TNBS intracolonic instillation. Macroscopic and microscopic damages, myeloperoxidase activity, cytokine levels, intestinal paracellular permeability, visceral sensitivity, faecal proteolytic activity and PAR-2 expression were assessed 24 h, 3 d and 5 d post-TNBS. FSG treatment improved the severity of colitis, by decreasing the TNBS-induced rise in gut permeability, visceral sensitivity, faecal proteolytic activity and PAR-2 expression at all post-TNBS points. All FSG effects were reversed by the ICI 182.780 except the decrease in faecal proteolytic activity and PAR-2 expression. In conclusion, the anti-inflammatory properties of FSG treatment result from two distinct but synergic pathways i.e an ER-ligand and a PAR-2 mediated pathway, providing rationale for potential use as adjuvant therapy in IBD.
Lara Moussa; Valérie Bézirard; Christel Salvador-Cartier; Valérie Bacquié; Corinne Lencina; Mathilde Lévêque; Viorica Braniste; Sandrine Ménard; Vassilia Théodorou; Eric Houdeau
Related Documents :
24908637 - Boswellia ovalifoliolata abrogates ros mediated nf-κb activation, causes apoptosis and...
23207147 - Interferon-λs: special immunomodulatory agents and potential therapeutic targets.
24596247 - Specific calcineurin targeting in macrophages confers resistance to inflammation via mk...
24399297 - The ubiquitin-specific protease usp15 promotes rig-i-mediated antiviral signaling by de...
12193227 - Endomorphins 1 and 2 inhibit il-10 and il-12 production and innate immune functions, an...
24908637 - Boswellia ovalifoliolata abrogates ros mediated nf-κb activation, causes apoptosis and...
Publication Detail:
Type:  Journal Article; Research Support, Non-U.S. Gov't     Date:  2012-11-14
Journal Detail:
Title:  PloS one     Volume:  7     ISSN:  1932-6203     ISO Abbreviation:  PLoS ONE     Publication Date:  2012  
Date Detail:
Created Date:  2012-11-20     Completed Date:  2013-06-20     Revised Date:  2013-07-11    
Medline Journal Info:
Nlm Unique ID:  101285081     Medline TA:  PLoS One     Country:  United States    
Other Details:
Languages:  eng     Pagination:  e49547     Citation Subset:  IM    
Neuro-Gastroenterology and Nutrition, Institut National de la Recherche Agronomique, UMR1331 Toxalim, INRA/INPT/UPS, Toulouse, France.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Cytokines / metabolism
Disease Models, Animal
Enzyme Activation / drug effects
Feces / enzymology*
Hyperalgesia* / therapy
Inflammatory Bowel Diseases / chemically induced,  metabolism*,  therapy
Intestinal Mucosa / drug effects,  metabolism*,  pathology
Peptide Hydrolases / metabolism*
Permeability / drug effects
Plant Extracts / administration & dosage*
Receptor, PAR-2 / metabolism
Soybeans / chemistry*
Trinitrobenzenesulfonic Acid / adverse effects
Weight Loss / drug effects
Reg. No./Substance:
0/Cytokines; 0/Plant Extracts; 0/Receptor, PAR-2; 2508-19-2/Trinitrobenzenesulfonic Acid; EC 3.4.-/Peptide Hydrolases

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Origin of Oryza sativa in China inferred by nucleotide polymorphisms of organelle DNA.
Next Document:  Serodiagnosis of tuberculosis in Asian elephants (Elephas maximus) in Southern India: a latent class...